Updated December 2020

Appendix 4.1 - CAP electronic Cancer Checklists

The College of American Pathologists (CAP) electronic Cancer Checklists (eCC) are a standardized list of common Question/Answer pairs used in reporting cancer surgical pathology data and were endorsed as a national standard by the Canadian Association of Pathologists on July 14, 2009. As of fiscal year 2010/11, CCO began implementing the CAP electronic Cancer Checklist standard with hospitals across the province. Now that all participating hospitals have completed implementation, the latest CAP eCC release is mandated across Ontario. The list of mandated CAP Cancer Checklists and Effective dates can be found in Appendix 4.1.  

To date, CCO Pathology Laboratory Medicine Program mandated use of 6 CAP biomarker templates; which became available in the October 2013 (Lung & CRC), December 2013 (Breast), June 2014 (Gastric HER2), July 2015 (Melanoma Biomarker Template), and July 2016 (Endometrium: Biomarker Reporting Template).

Body System

Mandated electronic Cancer Checklist (eCC)

Accepted eCC Release Versions

CAP original  Release Date

Effective Date

Bone and Soft Tissue

BONE: Resection

3.000.001

Jun-17

Apr-19

SOFT TISSUE: Resection

3.001.001

Aug-18

Apr-19

Breast

DCIS OF THE BREAST: Biopsy (recommended)

1.000.000

Feb-19

Apr-20

DCIS OF THE BREAST

3.001.001

Aug-19

Apr-20

INVASIVE CARCINOMA OF THE BREAST: Biopsy (recommended)

1.001.002

Apr-20

Apr-21

INVASIVE CARCINOMA OR THE BREAST

4.002.001

Feb-20

Apr-21

Central Nervous System

CNS: Histological Assessment

1.000.000

Aug-18

Apr-19

CNS: Integrated Diagnosis (Recommended)

1.000.000

Aug-18

Apr-19

Gastrointestinal

AMPULLA OF VATER: Ampullectomy, Pancreaticoduodenectomy (Whipple Resection)

3.000.002

Jul-17

Apr-18

ANUS: Abdominoperineal Resection

3.001.012

Sep-17

Apr-18

APPENDIX, NEUROENDOCRINE TUMOR (CARCINOID TUMORS): Excision (Appendectomy) or Resection

2.000.002

Jul-17

Apr-18

APPENDIX: Resection (Appendectomy with or without right hemicolectomy)

3.000.001

Jun-17

Apr-18

COLON AND RECTUM NEUROENDOCRINE TUMORS (Carcinoid Tumors): Resection, Including Transanal Disk Excision of Rectal Neoplasms

2.000.002

Jun-17

Apr-18

COLON AND RECTUM: Excisional Biopsy (Polypectomy)

2.010.001

Feb-20

Apr-21

COLON AND RECTUM: Resection, Including Transanal Disk Excision of Rectal Neoplasms

3.001.011

Aug-18

Apr-19

DISTAL EXTRAHEPATIC BILE DUCTS: Local or Segmental Resection, Pancreaticoduodenectomy

3.001.003

Aug-17

Apr-18

DUODENUM AND AMPULLA NEUROENDOCRINE TUMOR

1.000.001

Jun-17

Apr-18

ESOPHAGUS: Endoscopic Resection, Esophagectomy, or Esophagogastrectomy

3.002.001

Feb-20

Apr-21

GALLBLADDER: Resection/Cholecystectomy

3.000.001

Jun-17

Apr-18

GASTROINTESTINAL STROMAL TUMOR (GIST): Resection

3.001.001

Aug-18

Apr-19

HEPATOCELLULAR CARCINOMA: Hepatic Resection

3.004.001

Feb-20

Apr-21

INTRAHEPATIC BILE DUCTS: Resection

2.002.002

Apr-20

Apr-21

JEJUNUM AND ILEUM NEUROENDOCRINE TUMOR

1.000.001

Jul-17

Apr-18

PANCREAS (ENDOCRINE): Resection

3.000.002

Jul-17

Apr-18

PANCREAS (EXOCRINE): Resection

3.003.001

Feb-20

Apr-21

PERIHILAR BILE DUCTS: Local or Segmental Resection, Hilar Resection with or without Hepatic Resection

2.001.001

Jan-18

Apr-19

SMALL INTESTINE: Segmental Resection, Pancreaticoduodenectomy (Whipple Resection)

3.002.001

Feb-20

Apr-21

STOMACH, NEUROENDOCRINE TUMORS: Endoscopic Resection, Gastrectomy

2.000.002

Jul-17

Apr-18

STOMACH: Local Resection, Gastrectomy

3.002.001

Feb-20

Apr-21

Genitourinary

ADRENAL GLAND: Needle biopsy (Core, Incisional, Excisional); Resection

3.002.011

Feb-18

Apr-19

KIDNEY: Nephrectomy, Partial or Radical

3.002.002

Feb-18

Apr-19

PENIS: Incisional Biopsy, Excisional Biopsy, Partial Penectomy, Total Penectomy, Circumcision

3.001.001

Sep-17

Apr-18

PROSTATE GLAND: Radical Prostatectomy

3.003.001

Aug-19

Apr-20

RENAL PELVIS AND URETER: Resection

3.001.001

Sep-17

Apr-18

TESTIS: Radical Orchiectomy

3.002.001

Sep-17

Apr-18

TESTIS: Retroperitoneal Lymphadenectomy

3.001.001

Sep-17

Apr-18

URETHRA: Partial or Total Urethrectomy; Cystectomy, Cystoprostatectomy; Anterior Exenteration

3.002.011

Aug-18

Apr-19

URINARY BLADDER: Biopsy and Transurethral Resection of Bladder Tumor (TURBT)

1.004.001

Sep-17

Apr-19

URINARY BLADDER: Cystectomy, Partial, Total, or Radical; Anterior Exenteration

3.001.001

Sep-17

Apr-18

Gynecologic

ENDOMETRIUM: Hysterectomy, With or Without Other Organs or Tissues

3.002.001

Aug-18

Apr-19

OVARY or FALLOPIAN TUBE or PRIMARY PERITONEUM

1.003.001

Aug-19

Apr-20

TROPHOBLAST: Dilation and Curettage, Resection

3.000.001

Jun-17

Apr-18

UTERUS (SARCOMA): Hysterectomy & Myomectomy, with or without other organs or Tissues

2.001.001

Aug-18

Apr-19

UTERINE CERVIX: Trachelectomy, Hysterectomy, Pelvic Exenteration

4.000.001

Oct-20

Apr-21

VAGINA: Resection

3.004.001

Aug-19

Apr-20

VULVA

3.001.001

Aug-18

Apr-19

Head and Neck

LARYNX (SUPRAGLOTTIS, GLOTTIS, SUBGLOTTIS): Incisional Biopsy, Excisional Biopsy, Resection

3.002.001

Aug-18

Apr-19

LIP AND ORAL CAVITY: Incisional Biopsy, Excisional Biopsy, Resection

3.004.001

Feb-20

Apr-21

MAJOR SALIVARY GLANDS: Incisional biopsy, Excisional Biopsy, Resection

3.001.001

Aug-18

Apr-19

NASAL CAVITY AND PARANASAL SINUSES: Incisional Biopsy, Excisional Biopsy, Resection

3.002.001

Aug-18

Apr-19

PHARYNX (OROPHARYNX, HYPOPHARYNX, NASOPHARYNX): Incisional Biopsy , Excisional Biopsy, Resection

3.001.001

Aug-18

Apr-19

THYROID GLAND: Resection

4.003.001

Aug-19

Apr-20

Hematologic

BONE MARROW: Final Integrated Diagnosis (recommended)

1.000.000

Feb-19

Apr-20

BONE MARROW: Histologic Assessment (recommended)

1.000.000

Feb-19

Apr-20

HODGKIN LYMPHOMA: Biopsy, Resection

2.001.001

Oct-13

Apr-15

NON-HODGKIN LYMPHOMA/LYMPHOID NEOPLASMS: Biopsy, Resection

2.003.001

Oct-13

Apr-15

PLASMA CELL NEOPLASM: Targeted Biopsy, Resection, or Bone Marrow Sampling

1.002.001

Jan-18

Apr-19

Skin

MELANOMA OF THE SKIN: Excision, Re-Excision

2.001.001

Aug-18

Apr-19

MELANOMA OF THE SKIN: Biopsy

2.002.001

Aug-18

Apr-19

MERKEL CELL CARCINOMA OF THE SKIN: Incisional Biopsy, Excision, Re-Excision, Lymphadenectomy

2.001.001

Jan-18

Apr-19

Thorax

LUNG: Resection

3.005.021

Apr-20

Apr-21

MALIGNANT PLEURAL MESOTHELIOMA

3.001.001

Jan-18

Apr-19

THYMUS: Resection

3.001.001

Jan-18

Apr-19

Biomarkers

Bone Marrow: Biomarker Reporting Template (recommended)

1.000.000

Feb-19

Apr-20

BREAST: Biomarker Reporting Template

1.006.001

Feb-20

Apr-21

CNS: Biomarker Reporting Template (Recommended)

2.000.001

Aug-18

Apr-19

COLON AND RECTUM: Biomarker Reporting Template

1.001.001

Jan-15

Apr-18

DNA Mismatch Repair Biomarker Testing for Checkpoint Inhibitor Immunotherapy (Recommended)

1.000.011

Aug-18

Apr-19

Endometrium: Biomarker Reporting Template

1.000.000

Jul-16

Apr-20

LUNG: Biomarker Reporting Template

1.001.001

Jul-16

Apr-18

Melanoma: Biomarker Reporting Template

1.000.011

Aug-15

Apr-18

STOMACH: Gastric HER2 Biomarker Reporting Template

1.001.001

Jan-18

Apr-19

 

Note: Cancer Care Ontario will continue to exclude ALL biopsy pathology reports (synoptic and/or narrative format) from the pathology data quality indicators available in iPortTM.

The following electronic Cancer Checklists are  excluded from monthly reporting and are optional for use:

Body System

Excluded electronic Cancer Checklists (eCC)

Current Version

Bone and Soft Tissue

BONE: Biopsy

2.006.001

SOFT TISSUE: Biopsy

2.007.001

Gastrointestinal

ANUS: Excisional Biopsy or Local Excision (Transanal Disk Excision)

3.002.011

GASTROINTESTINAL STROMAL TUMOR (GIST): Biopsy

2.007.001

Genitourinary

KIDNEY: Biopsy

2.004.011

PROSTATE GLAND: Transurethral Prostatic Resection (TUR), Enucleation Specimen (Subtotal Prostatectomy)

2.008.001

PROSTATE GLAND: Needle Biopsy (OLD)

2.001.011

URETER, RENAL PELVIS: Biopsy

3.001.011

URETHRA: Biopsy

1.006.011

Gynecologic

UTERINE CERVIX: Excision (Cone/LEEP)

2.007.001

VAGINA: Biopsy

2.003.021

Ophthalmic

RETINOBLASTOMA: Enucleation, Partial or Complete Exenteration

3.001.011

UVEAL MELANOMA: Resection (Local Resection, Enucleation, Limited or Complete Exenteration)

3.001.011

Pediatric

EWING SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR: Biopsy

2.005.011

EWING SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR: Resection

2.006.011

new EXTRAGONADAL GERM CELL TUMOR: Biopsy

1.000.000

EXTRAGONADAL GERM CELL TUMOR: Resection

2.000.001

new HEPATOBLASTOMA (PEDIATRIC LIVER): Biopsy

1.000.000

HEPATOBLASTOMA (PEDIATRIC LIVER): Resection

3.000.001

new KIDNEY: Biopsy for Pediatric Renal Tumor

1.000.000

KIDNEY: Resection for Pediatric Renal Tumor

3.000.001

new NEUROBLASTOMA: Biopsy

1.000.000

NEUROBLASTOMA: Resection

3.000.001

new RHABDOMYOSARCOMA AND RELATED NEOPLASMS: Biopsy

1.000.000

RHABDOMYOSARCOMA AND RELATED NEOPLASMS: Resection

3.000.001

Other

new GENERAL TUMOR: Biopsy (recommended)

1.000.000

new GENERAL TUMOR: Resection (recommended)

1.001.001

Biomarker

GIST: Biomarker Reporting Template

1.002.011

Thyroid: Biomarker Reporting Template

1.001.001

 

Body System

Deprecated electronic Cancer Checklists (eCC)

eCC Checklist
template-id

Central Nervous System

BRAIN/SPINAL CORD: Biopsy/Resection

139.1000043

Gastrointestinal

SMALL INTESTINE NEUROENDOCRINE TUMOR

200.1000043

Genitourinary

PROSTATE GLAND: Needle Biopsy (Note A)

346.1000043

RENAL PELVIS: Resection/Nephroureterectomy, Partial or Complete

162.1000043

URETER: Resection

178.1000043

Gynecologic

FALLOPIAN TUBE: Unilateral Salpingectomy, Salpingo-oophorectomy, or Hysterectomy with Salpingo-oophorectomy

143.1000043

OVARY: Oophorectomy, Salpingo-Oophorectomy, Subtotal Oophorectomy or Removal of Tumor in Fragments, Hysterectomy with Salpingo-Oophorectomy

155.1000043

OVARY or FALLOPIAN TUBE: Oophorectomy, Salpingectomy, Salpingo-Oophorectomy, Subtotal Oophorectomy or Removal of Tumor in Fragments, Hysterectomy With Salpingo-Oophorectomy or Salpingectomy

257.1000043

Hematologic

BONE MARROW: Aspiration, Core (Trephine) Biopsy

137.1000043

OCULAR ADNEXA: Biopsy, Resection

192.1000043

Other

PERITONEUM: Resection

158.1000043

Skin

MELANOMA OF THE SKIN: Biopsy, Excision, Re-Excision

121.1000043

SQUAMOUS CELL CARCINOMA OF THE SKIN: Biopsy, Excision, Re-excision, Lymphadenectomy

165.1000043

Thorax

HEART: Resection

146.1000043

Biomarkers

Chronic Myelogenous Leukemia (CML): Biomarker Reporting Template

252.1000043

Chronic Lymphocytic Leukemia (CLL): Biomarker Reporting Template

251.1000043

Diffuse Large B-Cell Lymphoma (DLBCL): Biomarker Reporting Template

254.1000043

Myeloproliferative Neoplasms (MPN): Biomarker Reporting Template (Recommended)

250.1000043

 

CCO Monthly Synoptic DDF Reporting Inclusions

·         All CAP mandated eCCs for malignant surgical resections (that are applicable to your site)

·         In-situ resection reports for breast DCIS, urinary bladder, urethra and renal pelvis: ureter

·         Benign/borderline resection reports for brain and spinal cord

CCO Monthly Synoptic DDF Reporting Exclusions

·         All other benign, borderline, in-situ or metastatic reports (ICDO-3 behavior codes 0, 1, 2 and 6 respectively), with the exception those listed under inclusions

·         All biopsy, autopsy, cytology, gynecological cytology biomarker and flow cytometry reports will be electronically excluded if the hospital can send the correct report type in OBR 4

·         All hematopoietic checklists (bone marrow, Hodgkin lymphoma, non-Hodgkin lymphoma)

·         Consults completed on specimens from outside facilities

·         *Reports where diagnosis of cancer is uncertain (sent for consult)

·         *Squamous cell carcinoma cases where tumour thickness is <2cm (i.e. any squamous cell carcinoma less than pT2)

·         *Re-excisions (except for re-excisions for melanoma and SCC of the skin which are required in DDF format using the appropriate eCCs)

*These are examples of the exclusions that the current CAP checklist DDF templates may not or cannot be appropriately utilized by the reporting pathologists and which CCO cannot electronically exclude from the Synoptic Pathology Reporting Indicator. These exclusions fall into the 10% window.

Print This Page